Cargando…

Dolutegravir for second-line treatment: Programmatic implications of new evidence

Detalles Bibliográficos
Autores principales:	Zhao, Ying, Maartens, Gary, Meintjes, Graeme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AOSIS 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559621/ https://www.ncbi.nlm.nih.gov/pubmed/36299553 http://dx.doi.org/10.4102/sajhivmed.v23i1.1428

Ejemplares similares

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
por: Mahomed, Kairoonisha, et al.
Publicado: (2020)

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
por: Keene, Claire M, et al.
Publicado: (2023)

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial
por: Zhao, Ying, et al.
Publicado: (2023)

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
por: Zhao, Ying, et al.
Publicado: (2021)

Weight gain on dolutegravir: Association is not the same as causation
por: Maartens, Gary, et al.
Publicado: (2023)

Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial
por: Griesel, Rulan, et al.
Publicado: (2021)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021)

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial
por: Griesel, Rulan, et al.
Publicado: (2023)

A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy
por: Cohe, Karen, et al.
Publicado: (2019)

Outcome of patients on second line antiretroviral therapy under programmatic condition in India
por: Chakravarty, Jaya, et al.
Publicado: (2015)

Clofazimine for the treatment of tuberculosis
por: Stadler, Jacob A. M., et al.
Publicado: (2023)

Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study
por: Meintjes, Graeme, et al.
Publicado: (2015)

Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
por: Moorhouse, Michelle A., et al.
Publicado: (2018)

Student assessment: Moving over to programmatic assessment
por: Singh, Tejinder
Publicado: (2016)

Risk of immune reconstitution inflammatory syndrome with integrase inhibitors versus other classes of antiretrovirals: a systematic review and meta-analysis of randomised trials
por: Zhao, Ying, et al.
Publicado: (2022)

Programmatic Evaluation: A Prospect in Program Evaluation Design
por: Al Sinani, Siham, et al.
Publicado: (2021)

Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho
por: Tschumi, Nadine, et al.
Publicado: (2023)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial
por: Bevers, Lisanne A H, et al.
Publicado: (2023)

Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV
por: Mondleki, Enkosi, et al.
Publicado: (2022)

Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: A cross-sectional study
por: Meintjes, Graeme, et al.
Publicado: (2008)

Operational Research to Inform Programmatic Approaches to the Management of Tuberculosis in Uzbekistan
por: Gadoev, Jamshid, et al.
Publicado: (2021)

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)

Second-Line Antiretroviral Therapy in Sub-Saharan Africa: It Is Time to Mind the Gaps
por: Murphy, Richard A., et al.
Publicado: (2017)

Second-line treatment for renal cell cancer
por: Di Lorenzo, G, et al.
Publicado: (2012)

A multi-parameter diagnostic clinical decision tree for the rapid diagnosis of tuberculosis in HIV-positive patients presenting to an emergency centre
por: van Hoving, Daniël Jacobus, et al.
Publicado: (2022)

Programmatic Responses to the Coronavirus Pandemic: A Survey of 502 Cardiac Surgeons
por: Seese, Laura, et al.
Publicado: (2020)

Measuring Learning of Medical Students through ‘Programmatic Assessment'
por: Khan, Rehan Ahmed
Publicado: (2018)

Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens
por: Fokam, Joseph, et al.
Publicado: (2023)

Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania
por: Ntamatungiro, Alex J, et al.
Publicado: (2023)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

2023 Southern African HIV Clinicians Society Adult Antiretroviral Therapy Guidelines: What’s new?
por: Nel, Jeremy, et al.
Publicado: (2023)

Which second line treatments after ESA failure?
por: Park, Sophie, et al.
Publicado: (2017)

Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases
por: Cevik, Muge, et al.
Publicado: (2020)

Blended programmatic assessment for competency-based curricula: Is it the way forward?
por: Iyer, PB
Publicado: (2021)

Validity evidence for programmatic assessment in competency-based education
por: Bok, Harold G. J., et al.
Publicado: (2018)

Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV
por: Banda, Clifford G., et al.
Publicado: (2022)

Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral therapy in South Africa: a retrospective cohort study
por: Asare, Kwabena, et al.
Publicado: (2023)

Utility of Second-Generation Line Probe Assay (Hain MTBDRplus) Directly on 2-Month Sputum Specimens for Monitoring Tuberculosis Treatment Response
por: Rockwood, Neesha, et al.
Publicado: (2017)

Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil
por: Diaz, Ricardo Sobhie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fdrqd8t1scfrhupv7q5i34vknd